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ABSTRACT
Background: Recently cardiometabolic risk reduction has been observed in patients with slightly elevated 
bilirubin concentration, as well as increased risk in subjects with excessive iron reserves. The aim of this 
study was to evaluate the relationship between overweight and/or abdominal obesity, serum bilirubin and 
selected iron status indicators levels in non-obese subjects.
Methods: The study group consisted of 80 healthy, non-obese subjects aged 25–40 years. In all subjects 
total and direct bilirubin (T-BIL, D-BIL), iron (Fe), transferrin (TRSF), ferritin (FERR) and hepcidin (HEPC) 
measurements were performed. Anthropometric parameters (BMI, waist circumference, WHR) were 
measured and body composition (% of body fat, muscles and level of visceral fat) was evaluated using 
body segment analyzer.
Results: Men showed significantly higher values of waist circumference, WHR, muscle mass, visceral fat 
level and FERR and HEPC concentrations, compared to women. Lower concentrations of T-BIL, D-BIL and 
higher concentration of FERR, HEPC occurred in the overweight group. In all subjects and in the overweight 
group T-BIL, D-BIL showed negative correlations with BMI, waist circumference, fat mass and visceral fat 
level, while for FERR, HEPC those correlations were positive. Overweight subjects had an approximately 
4-fold higher incidence of low T-BIL, D-BIL levels (p < 0,001), as well as nearly 2-fold higher incidence of 
high transferrin level (p = 0,02).
Conclusions: Overweight subjects have lower bilirubin levels and higher levels of factors potentially contrib-
uting to increased oxidative stress, for example ferritin and hepcidin. Serum bilirubin, ferritin and hepcidin 
concentration are related to body composition indicators, particullary fat mass and visceral fat level.
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INTRODUCTION
The incidence of overweight and obesity has 
increased threefold in the last twenty years, which is 
a serious health and socio-economic problem. Obesity 
is involved in the pathogenesis of numerous diseases 
such as: type 2 diabetes, metabolic syndrome, hyper-
tension, myocardial infarction, ischemic stroke and 
cancer. In the course of those diseases, inflammatory 
processes and increased production of free radicals 
are of great importance. Research over the past sev-
eral years indicate the protective effect of bilirubin, 
as a low-molecular antioxidant, on reducing the risk 
of cardiovascular disease [1]. In its pathogenesis 
attention was also paid to the important role of iron 
oxidation processes, leading to increased synthesis 
of free radicals.
Bilirubin is a product of oxidative heme metabolism 
in mammals [2]. In this process heme is obtained 
mainly from hemoglobin, in smaller quantities from 
other proteins containing heme, i.e. myoglobin and 
cytochrome P-450 [3]. During its metabolism, bilirubin 
is modified by esterification with glucuronic acid. The 
consequence of this process is the formation of ionic 
derivatives, mono- and diglucuronides, which are 
excreted together with the bile. It is one of the most 
important biochemical parameters used to diagnose 
liver and bile ducts function [4].
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Iron is a very important micronutrient for living or-
ganisms. It is a cofactor for many proteins of various 
biological significance. It plays a key role in the forma-
tion of hemoglobin, myoglobin and many important bio-
chemical pathways, including energy metabolism, the 
production of neurotransmitters and the function of the 
immune system. As the transition metal, iron has useful 
binding properties to redox ligands [5]. Physiologically, 
the total iron content in the body of an adult male is 
about 4 g, in women about 3.5 g. The metabolically 
active iron constitutes 80% of the total pot, and in this 
70% is contained in hemoglobin. Iron stored in ferritin 
accounts for approx. 20% Only a small percentage of 
iron is associated with transferrin (transport protein) [6].
Studies show that low bilirubin concentration in vivo 
eliminates free oxygen radicals and thus leads to allevi-
ation of oxidative stress. The unconjugated bilirubin has 
the property to „sweep” singlet oxygen. In the presence 
of hydrogen peroxide or organic hydroxides, bilirubin 
behaves like a reducing agent for some peroxidases, 
thus minimizing the amount of potential oxidants [7]. In 
vitro studies have shown that bilirubin combined with 
albumin removes superoxide radicals from lysosomal 
systems and homogeneous solutions [8]. The reduction 
of inflammatory response in the vascular wall, resulting 
from the elimination of oxidative stress and the inhibition 
of endothelial cell activation, is associated with both 
bilirubin and its derivative, biliverdin [7]. Overexpression 
of heme oxygenase-1 (HO-1), an enzyme that catalyzes 
the breakdown of heme, reduces the production of 
inflammatory mediators, as well as indirectly affects 
vasodilation, stimulating the expression and production 
of nitric oxide [9]. Using its antioxidant activity, bilirubin 
can reduce lipid oxidation by eliminating free radicals 
and inactivating oxidized lipoproteins (especially LDL) 
and lipids, resulting in the inhibition of atherosclerotic 
plaque production [10]. In addition, the plasma concen-
tration of bilirubin correlates inversely with many risk 
factors for coronary heart disease, including smoking, 
increased LDL-cholesterol, diabetes, and obesity, while 
it is positively correlated with HDL cholesterol, which 
has cardioprotective properties [11].
Excess iron level is considered to be harmful, be-
cause it promotes the formation of free radicals, which 
leads to tissue damage or oxidative stress [12]. Free 
radicals cause damage to molecules such as proteins, 
lipids and DNA. Such damaged biomolecules may be 
involved in the pathogenesis of numerous diseases, 
for example through co-participation in the process of 
atherosclerotic plaque formation. [13]. Epidemiological 
studies have also shown that high levels of iron in the 
body are associated with increased risk of coronary 
artery disease [12]. The largest source of iron is the 
breakdown of heme. During normal metabolism, iron is 
bound by ferritin to protect cells. In plasma, it is bound 
and transported by transferrin [7].
Iron as a free active metal occurs in very small 
amounts. Free iron along with hydrogen peroxide and 
superoxide anion radical in the Haber-Weiss reaction 
produce a very toxic hydroxyl radical (OH). The OH 
radical may be the initiator of lipid peroxidation, by 
separating the hydrogen atom from the polyunsaturat-
ed fatty acid molecule. The lipid peroxides formed in 
this process with the participation of iron may initiate 
additional lipid peroxidation [13]. OH also leads to LDL 
peroxidation, low density lipoprotein molecules. This 
process leads to the formation of oxidized LDL (ox-LDL) 
with strong atherogenic properties [6]. 
Several studies suggest that in overweight/obese 
subjects iron deficiency is more common, as well as 
higher ferritin levels. Therefore it seems that the pro-ox-
idative effects of iron and its relationship to adipose 
tissue depend not on its serum concentration, but 
primarily on the iron storage pool [14].
According to recent studies, inflammatory activity 
of adipose tissue may be strongly associated with dis-
turbances of endogenous antioxidants and potential 
oxidants, including bilirubin and iron, which is why their 
determination may be important in assessing the risk 
of cardiometabolic disorders. The aim of the study was 
to evaluate the relationship between overweight and/or 
abdominal obesity, serum bilirubin and selected iron 
status indicators (iron, transferrin, ferritin, hepcidin) 
concentration in non-obese, non-smoking subjects with 
normal fasting glycaemia.
Subjects, materials and methods
Study consisted of 80 non-obese (BMI 18.5–
27.0 kg/m2), non-smoking and normoglycemic (fasting 
glucose 60–99 mg/dL) subjects aged 25–40 years 
(40 women, 40 men). Basic anthropometric measure-
ments (body weight, waist circumference, BMI, WHR), 
blood pressure measurements with an automatic blood 
pressure monitor Omron M6 Comfort (Omron Health-
care, Kyoto, Japan) and medical history of chronic 
diseases were performed. 
Serum and fluoride plasma were collected in the 
morning (7.00–9.00 am) after 12 hours of fasting. 
Samples were centrifuged in low temperature (4°C). 
Laboratory tests: plasma glucose and total and direct 
bilirubin (T-BIL, D-BIL), iron (Fe), transferrin (TRSF) 
and ferritin (FERR) in serum were performed on ABX 
Pentra 400 autoanalyzer (Horiba Ltd., Kyoto, Japan). 
Serum samples were divided into small aliquots and 
were frozen in -70°C to avoid peptides degradation 
for further assays. Concentration of serum hepcidin 
(HEPC) was determined using Hepcidin 25 (Bioactive) 
HS enzyme-linked immunosorbent assay (ELISA) kit 
(DRG Diagnostics GmbH, Marburg, Germany). The limit 
of detection was 0.30 ng/mL.
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All laboratory measurements were performed in 
the Department of Laboratory Medicine, Nicolaus Co-
pernicus University Collegium Medicum in Bydgoszcz, 
Poland.
Body composition (percentage of body fat, mus-
cles and level of visceral fat) was evaluated using 
body segment analyzer based on electrical bio-
impedance (BIA) technology (InnerScan V BC-545N, 
Tanita). Measurements were performed fasting, in the 
morning, directly before blood samples collection 
and in accordance with the manufacturer’s instruc-
tions. The reference values of these parameters 
depend on age and for 25–40 year olds the follow-
ing values were adopted: fat mass women 21–33%, 
men 8–20%; level of visceral fat: 1–12; muscle mass 
women > 24%, men > 33% (according to manufac-
turer’s manual).
Statistical analysis was performed using STATISTI-
CA 12.0 PL software (StatSoft Inc. 2014). Data were pre-
sented as mean±standard deviation (normal distribu-
tion) or median and 25th–75th percentile (non-Gaussian 
distribution). Differences between study groups were 
calculated by t-Student, U-Mann-Whitney and ANOVA 
Kruskal-Wallis tests. P value < 0.05 was considered 
statistically significant.
The study was approved by the Bioethics Commit-
tee at the Nicolaus Copernicus Univeristy Collegium 
Medicum in Bydgoszcz, Poland (No. KB 627/2010) 
and complied with the World Medical Association 
Declaration of Helsinki regarding ethical conduct 
of research involving human subjects. From all par-
ticipants involved in this study an informed written 
consent was obtained.
Results
In the study group, total bilirubin concentrations 
ranged 10.9–17.8 μmol/L. Higher, but statistically 
insignificant, medians of total and direct bilirubin and 
iron were observed in men, compared to women (Table 
1). In women statistically significantly lower values of 
the following parameters were found: waist circum-
ference, WHR, muscle mass, level of visceral tissue, 
ferritin and hepcidin. Table 2 shows the comparison 
of the measured parameters in subjects with normal 
body weight and overweight. Statistically significant 
higher concentrations of total and direct bilirubin were 
observed in normal weight subjects. In contrast, over-
weight subjects have significantly higher concentrations 
of ferritin and hepcidin.
In the analysis of the relationship between body 
composition and biochemical parameters (Table 3), 
positive correlations between ferritin and hepcidin with 
waist circumference, WHR, fat mass and level of visceral 
fat were observed. However, a negative correlation 
was found between total and direct bilirubin with BMI, 
waist circumference, fat mass and level of visceral fat. 
In addition, total bilirubin and hepcidin showed signif-
icant relationships with muscle mass. Iron correlated 
weakly only with fat mass. The correlation was analyzed 
also in the group of subjects with normal weight and 
overweight. In subjects with normal body weight, only 
negative correlations of total and direct bilirubin with 
BMI (R = -0.48 and -0.40; p < 0,001, respectively) and 
waist circumference were observed (R = -0.32 and 
-0.35; p < 0.05, respectively) and positive weak cor-
relation of ferritin and hepcidin with waist circumference 
Table 1. Clinical and biochemical characteristics of study group
Variables Study group (n = 80) Women (n = 40) Men (n = 40) p
Age (years) 31 (27–35) 32 (26–37) 30 (27–33) ns
BMI [kg/m2] 24.3 (± 3.04) 24,33 (± 3.53) 24,28 (± 2,51) ns
Waist [cm] 87 (76–91.5) 78.5 (70–89) 88,5 (84–93) 0,001
WHR 0,83 (± 0.07) 0,78 (± 0,06) 0,87 (± 0,05) < 0,001
Fat mass [%] 24.4 ± 6.6 28.2 ± 5.4 20.6 ± 5.4 < 0,001
Muscle mass [%] 46 ± 12.5 40 ± 3.3 51.9 ± 7.7 < 0,001
Visceral fat level 4.0 (2.3–6.0) 2.8 (1.5–4.0) 5,75 (4,0- 8,0) < 0,001
T-BIL [µmol/L] 13.2 (10.9–17.8) 12,3 (8,7-17,9) 15,4 (12,3-17,8) ns
D-BIL (µmol/L) 2.7 (2.2–3.6) 2.6 (2.1–3.4) 3.1 (2.4–3.6) ns
Fe (µmol/L) 17.8 (± 5.9) 16.8 (± 5.7) 18.8 (± 6.1) ns
TRSF (µmol/L) 32.2 (29.1–36.2) 33.3 (28.3–39.3) 30.5 (29.3–33.9) ns
FERR (nmol/L) 1,31 (0.64–2.31) 0,70 (0,44–1,21) 1,84 (1.35–2.65) < 0,001
HEPC (ng/mL) 19.4 (8.4–33.2) 12.9 (4.9–24.0) 27,6 (16.6–35.4) 0,002
Data presented as mean ± SD or median (25–75%) 
ns — statistically insignificant (p > 0,05)
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Age (years) 28 (26–32) 33 (27–37) 0,048
BMI [kg/m2] 21,88 (± 1,86) 26,73 ± 1,76 < 0,001
Waist [cm] 77.5 (68–84) 91 (87–94) < 0,001
WHR 0.8 ± 0.07 0,85 (± 0,06) 0,002
Fat mass [%] 20.5 (16.2–26.5) 24.4 (21.1–29.0) 0,03
Muscle mass [%] 49.0 (39.2–57.6) 40,2 (32.2–51.5) 0,02
Visceral fat level 3.0 (2.0–5.0) 7.5 (2.5-11.0) < 0,001
T-BIL [µmol/L] 16.6 (12.5–19.5) 12.1 (8.4–14.4) < 0,001
D-BIL [µmol/L] 3.2 (2.7–3.9) 2.4 (1.8–3.1) < 0,001
Fe [µmol/L] 19.1 ± 6.3 16.6 (± 5.3) ns
TRSF (µmol/L) 31.4 (28.3–33.5) 33.4 (29.8–37.4) ns
FERR (nmol/L) 1,14 (0,59–2,18) 1,33 (1.15–2.33) 0,03
HEPC (ng/mL) 14.3 (7.2–25.1) 23.2 (13.8–32.2) 0,02
ns — not significant differences (p > 0,05)
Table 3. Selected correlation coefficient values in study group (log10 — transformed variables)
Variables T-BIL D-BIL Fe TRSF FERR HEPC
BMI -0,48** -0,4* ns ns ns ns
Waist -0,32* -0,35* ns ns 0,29* 0,37**
WHR ns ns ns ns 0,32* 0,33*
Fat mass [%] -0,36* -0,31* -0,26* ns 0,32* 0,44**
Muscle mass [%] 0,31* ns ns ns ns -0,30*
Visceral fat level -0,42** -0,29* ns -0,28* 0,31 0,38**
*p < 0,05; **p < 0,001
Table 4. Correlation between body composition and selected biochemicals parameters in overweight subjects
Variables T-BIL D-BIL FERR HEPC
BMI -0,48** -0,40** ns ns
Waist -0,32* -0,35* 0,29* 0,37*
WHR ns ns 0,32* 0,33*
Fat mass [%] -0,45** -0,42** 0,35* 0,46**
Muscle mass [%] 0,42** ns ns -0,42**
Visceral fat level -0,38* -0,26* 0,36* 0,40**
*p < 0,05; **p < 0,001
(data not presented). In the overweight group (Table 
4) both total and direct bilirubin were correlated with 
BMI, waist circumference, fat mass and level of visceral 
fat. However, ferritin and hepcidin showed opposite 
relationships with body composition. In addition, a sig-
nificant relationship was found between total bilirubin 
and hepcidin with muscle mass (R = 0.42 and -0.41; 
p < 0,001, respectively).
The frequency of selected biochemical changes 
in individuals with normal weight and overweight was 
compared. Low values, corresponding to first tertile, 
were used for total and direct bilirubin and iron. A higher 
Katarzyna Bergmann et al., Serum bilirubin, iron status indicators and body composition
185www.journals.viamedica.pl/medical_research_journal
Figure 1. Prevalence of low T-BIL, D-BIL, Fe and high FERR and HEPC levels in normal weight and overweight subjects
Figure 2. Difference in transferrin levels in subject with (1) 
and without (0) abdominal obesity
percentage of subjects with low total (< 12,1 μmol/L) 
and direct (< 2.4 μmol/L) bilirubin was observed in the 
overweight group, as well as tendency for low levels 
of iron (< 14.9 μmol/L). Hepcidin and ferritin concen-
tration values corresponding to their third tertile (> 
28.18 ng/mL; >1.74 nmol/L) were found more often in 
overweight subjects (41.6% and 47.2%, respectively), 
compared to normal weight group. In addition, statis-
tically significant higher concentration of transferrin 
(Figure 2) was observed in patients with abdominal 
obesity, defined by waist circumference (≥ 80 cm in 
women and ≥ 94 cm in men).
Discussion
Bilirubin, the final product of heme metabolism, for 
many years was considered a toxic, side product. How-
ever, studies from the last years suggest that bilirubin is 
a strong endogenous antioxidant [15]. It belongs to the 
low molecular weight antioxidants, which low concentra-
tions protect against oxidation or delays this process. This 
group also includes compounds such as: glutathione, 
uric acid, carnitine, flavonoids and vitamins A, C and E.
Obesity, especially of the abdominal type, is associ-
ated with low-grade inflammation in adipocytes. Inflam-
mation leads to the development of insulin resistance 
and type 2 diabetes. Adipocytes in obese subjects 
produce large amounts of proinflammatory cytokines: 
TNF-a (tumor necrosis factor a) and interleukin 6, 
whose concentration is under physiological condi-
tions decreased by HO-1, involved in the synthesis 
of bilirubin. It can be assumed that in obese subjects, 
the concentration of bilirubin in the blood may be 
lower than in people with normal body weight [16]. 
Oxidative stress initiated by the iron oxidation activity 
is involved in the pathogenesis of many diseases, i.e. 
diabetes or atherosclerosis [13]. A common risk factor 
in these diseases is also overweight or obesity, which 
also affect iron metabolism. In obese subjects hepcidin 
concentration, produced by adipocytes, is significantly 
increased. It inhibits the intestinal absorption of iron and 
its release from macrophages and liver, leading to its 
accumulation in the body [17]. Therefore, it is suggested 
that overweight or obese individuals may have higher 
values of iron status indicators, which may reflect an 
increased risk of cardiometabolic disorders.
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In this study, overweight subjects had statistically 
significantly lower total and direct bilirubin concentra-
tions. Andersson et al. stated that the lower body fat 
content and weight loss are associated with increased 
bilirubin [18]. Similarly, Swift et al. observed that aerobic 
physical training has a beneficial effect on body weight, 
and thus may increase the concentration of bilirubin 
[19]. In the last years, attention has been paid to the 
relationship between Gilbert’s syndrome and the risk 
of ischemic heart disease. Maruhasi et al. in their study 
showed that patients with Gilbert’s syndrome have low 
oxidative stress, resulting from genetically conditioned 
hyperbilirubinemia, which protects endothelium. This 
beneficial effect on blood vessels may contribute to the 
reduction of vascular complications in atherosclerosis in 
patients with Gilbert’s syndrome, compared to patients 
without the syndrome [20]. There is increasing evidence 
that moderately elevated concentrations of iron stores, 
below the values found in genetic hemochromatosis, 
may adversely affect the cardiovascular system as well 
as lipid and carbohydrate metabolism. In population 
studies, elevated levels of ferritin have been shown to 
be associated with hypertension, dyslipidemia, elevated 
insulin and glucose, and abdominal obesity. In several 
studies, the relation between elevated iron concentra-
tion and the occurrence of metabolic syndrome was 
also observed [21].
Serum ferritin concentration is a good indicator of 
iron stores in the body. Epidemiological studies have 
shown that increased ferritin levels are associated 
with an increased cardiometabolic risk [22]. In this 
study, significant differences in the concentration of 
ferritin were observed, depending on the sex and BMI 
values. De Goda et al. reported a relationship between 
high ferritin concentration and the degree of coronary 
stenosis in women with obstructive coronary artery 
disease. In the case of men, its concentration was 
not a prognostic element of the degree of vessel ob-
struction [23]. Escobar-Morreale et al. also observed 
higher concentration of ferritin in the group of women 
with polycystic ovary syndrome and overweight than 
in women with normal body weight [24]. The relation-
ship between ferritin concentration and obesity was 
also noted in the study by Williams et al. The study 
group consisted of 815 young men and women under 
26 years of age. In women, ferritin correlated with waist 
circumference, BMI, triglycerides and C-reactive protein 
(CRP) concentration [25]. It is worth noting that ferritin 
may be treated as an indicator of inflammation, which 
is increased in abdominal obesity and results from the 
pro-inflammatory activity of visceral adipose tissue.
Several studies suggest a connection between 
iron deficiency and overweight/obesity. In a study 
conducted by Nead et al. on the overweight children 
and adolescents group, iron deficiency was observed 
frequently in this group. The incidence of iron deficiency 
increased with the increase in BMI values [26]. The high-
er incidence of iron deficiency in overweight children 
and adolescents compared to the normal body group 
was also found in the study by Pinhas-Hamiel et al. In 
the study, higher iron concentrations were also ob-
served in the normal body group [27]. The association 
of iron deficiency with obesity is explained in several 
ways. Due to the overexpression of hepcidin in obese 
people, intestinal iron absorption is inhibited. Moreover, 
on account of low-grade inflammation, the iron does not 
fulfill its physiological role [28].
Hepcidin is recently consider as one of the most 
important regulators of iron metabolism. Cheng et al. 
showed in their study the relationship between obesity 
and minor disturbances of iron metabolism. In the group 
of healthy young women with overweight and obesity, 
the median concentration of hepcidin was 6.4 ng/mL. 
The lowest concentrations of hepcidin were observed 
in subjects with lower iron concentrations [29]. How-
ever, in a population study conducted on a group of 
1391 individuals, Martinelli et al. noted an elevated 
concentration of hepcidin in patients with metabolic 
syndrome. For both women and men, the hepcidin 
concentration increased with increasing concentration 
of classic risk factors, as well as of ferritin. In addition, 
it was concluded that in the metabolic syndrome, the 
hepcidin concentration gradually increases in response 
to a moderate increase in iron stores in the body [30]. 
The results of own research in the group of healthy, 
young people allow to determine the relationship be-
tween the weight, body composition and the concentra-
tion of both total and direct bilirubin, as well as selected 
iron status indicators, particularly the concentration of 
ferritin and hepcidin. The interaction between oxidative 
stress, inflammation and iron metabolism has not been 
fully understood, which makes it difficult to determine 
the exact role of iron as a cardiometabolic risk factor. 
The results obtained in this study may suggest an im-
portant role of the analyzed parameters in the diagnosis 
of cardiometabolic disorders. However, despite the 
promising results in this study, attention should be paid 
to its limitations, especially a small number of respon-
dents. Therefore, the results would require verification 
in a large population-based study.
Disclosure of interest: The authors state that there 
are no conflicts of interestregarding the publication of 
this article.
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D-BIL – direct bilirubin
ELISA — enzyme-linked immunosorbent assay
Fe — iron
FERR — ferritin
HDL — high-density lipoprotein
HEPC — hepcidin
HO-1 — heme oxygenase-1
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